- Home
- BDTX vs SCLX Comparison
BDTX vs SCLX Comparison
Compare BDTX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- SCLX
- Stock Information
- Founded
- BDTX 2014
- SCLX 2011
- Country
- BDTX United States
- SCLX United States
- Employees
- BDTX N/A
- SCLX N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- SCLX Health Care
- Exchange
- BDTX Nasdaq
- SCLX Nasdaq
- Market Cap
- BDTX 161.6M
- SCLX 130.1M
- IPO Year
- BDTX 2020
- SCLX N/A
- Fundamental
- Price
- BDTX $2.62
- SCLX $0.61
- Analyst Decision
- BDTX Strong Buy
- SCLX Strong Buy
- Analyst Count
- BDTX 4
- SCLX 3
- Target Price
- BDTX $15.50
- SCLX $11.33
- AVG Volume (30 Days)
- BDTX 591.8K
- SCLX 184.3K
- Earning Date
- BDTX 11-05-2024
- SCLX 11-26-2024
- Dividend Yield
- BDTX N/A
- SCLX N/A
- EPS Growth
- BDTX N/A
- SCLX N/A
- EPS
- BDTX N/A
- SCLX N/A
- Revenue
- BDTX N/A
- SCLX $50,833,000.00
- Revenue This Year
- BDTX N/A
- SCLX $32.77
- Revenue Next Year
- BDTX N/A
- SCLX $50.71
- P/E Ratio
- BDTX N/A
- SCLX N/A
- Revenue Growth
- BDTX N/A
- SCLX 9.41
- 52 Week Low
- BDTX $2.09
- SCLX $0.54
- 52 Week High
- BDTX $7.66
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- BDTX 31.71
- SCLX 28.71
- Support Level
- BDTX $3.16
- SCLX $0.73
- Resistance Level
- BDTX $3.44
- SCLX $1.14
- Average True Range (ATR)
- BDTX 0.22
- SCLX 0.11
- MACD
- BDTX 0.03
- SCLX -0.04
- Stochastic Oscillator
- BDTX 0.61
- SCLX 11.99
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.